Loading
Stereotactic body radiotherapy converges multiple beams with sub-millimetre accuracy to deliver tumour-destroying doses in one to five outpatient sessions, doing the job of surgery for inoperable early lung cancer and for metastases in liver, spine and brain. Tumour size and location limit its use, and late toxicity is a concern near the central airways.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
Stereotactic body radiotherapy delivers ablative doses in 1-5 sessions by converging multiple non-coplanar beams with sub-millimetre accuracy, producing steep dose gradients that spare surrounding tissue. It is standard for inoperable early lung cancer, oligometastatic disease, liver, spine, and brain metastases (radiosurgery). SABR-COMET showed an overall survival benefit in oligometastatic disease, which underpins the idea of metastasis-directed therapy. Treatment is outpatient with minimal recovery, and SBRT pairs with immunotherapy in the hope of abscopal effects, though that benefit remains unproven in randomised trials. Limits are tumour size and location, with late toxicity a concern near central airways. The simple version is a few very high, very precise doses that can ablate a tumour much as surgery would.
Multiple non-coplanar beams converge with sub-millimetre accuracy; steep dose gradients.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"stereotactic body radiotherapy" OR ABSTRACT:"stereotactic body radiotherapy" OR TITLE:"stereotactic ablative radiotherapy" OR ABSTRACT:"stereotactic ablative radiotherapy" OR TITLE:"SBRT" OR ABSTRACT:"SBRT" OR TITLE:"SABR" OR ABSTRACT:"SABR"). Results are unfiltered search hits about SBRT / SABR (stereotactic radiotherapy), not a curated reading list.
Shares Amar U. Kishan, CROSSFIRE, A regulatory pathway for new radiotherapy techniques modelled on drug development, ViewRay (MRIdian).
Shares Brainlab, Prizes for unpatentable surgical and radiotherapy techniques proven in trials, Partial nephrectomy, ablation & active surveillance of small renal masses, Rajiv Gandhi Cancer Institute and Research Centre.
Shares A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer, Central-boost Ablative Radiation Therapy for Solid Tumors (CBART), Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers, Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic.
Shares Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy, JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer, Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC., Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT.
Shares Hacettepe University Cancer Institute, Koo Foundation Sun Yat-Sen Cancer Center, Radiotherapy for everyone who needs it by 2040, Centre Oscar Lambret.
Shares Joe Y. Chang, Theodore S. Hong, Hokkaido University Hospital, Proton arc therapy.
Shares Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM, Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial, Partial nephrectomy, ablation & active surveillance of small renal masses, Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis.